HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SCNX
Scienture Holdings, Inc.
There isn't enough reported data to score SCNX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SCNX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
SCNX's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SCNX PE Valuation
SCNX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SCNX Forward outlook
There aren't enough analyst estimates for SCNX to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SCNX Earnings Per Share
SCNX and HIMS do not have enough comparable growth data to identify a winner.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
SCNX has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus up 3,250% for SCNX.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over SCNX on profitability, with a higher operating margin.
SCNX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $56.3K | +449% |
| Q3 2025 | $590.1K | +810% |
| Q4 2024 | $53.1K | -98% |
| Q3 2024 | $64.9K | -97% |
| Q2 2024 | $18.7K | -99% |
| Q4 2023 | $2.4M | -7% |
| Q3 2023 | $2.1M | -14% |
| Q2 2023 | $2.3M | -31% |
SCNX's revenue is recovering but still below its 2020 peak: $343,639 last quarter, up 3250% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -786% | +34029 points |
| Q1 2026 | -6231% | +1709 points |
| Q3 2025 | -739% | +4654 points |
| Q1 2025 | -34815% | N/A |
| Q4 2024 | -7940% | -7676 points |
| Q3 2024 | -5393% | -5352 points |
| Q2 2024 | -7999% | -7983 points |
| Q4 2023 | -263% | -186 points |
SCNX's operating margin was −786% last quarter, up 7154 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the stronger cash trend. Its trailing FCF is down 84% versus its history, compared with SCNX at down 170%.
SCNX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.1M | -$1.1M |
| Q1 2026 | -$2.9M | +$37.2K |
| Q2 2025 | -$2M | -148% |
| Q1 2025 | -$3M | +$7.2M |
| Q4 2024 | -$2.9M | -$1.9M |
| Q2 2024 | $4.2M | +1185% |
| Q1 2024 | -$10.2M | -$9.3M |
| Q4 2023 | -$980.2K | -180% |
SCNX has burned cash in most quarters: −$11M over the past year, against −$10M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SCNX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SCNX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.5% | -40.6K shares |
| 1 year | +320% | +1.2M shares |
SCNX has 2M diluted shares, up 320% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SCNX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2020 | -52.5x | Net Cash |
| Q4 2019 | -20.3x | Net Cash |
SCNX has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SCNX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.1 | Oversold |
| Stochastic | 5.1 | Oversold |
SCNX's weekly RSI is 28 (oversold) and its Stochastic is 5 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SCNX PE vs Healthcare Sector
SCNX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
SCNX has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus SCNX above 0 of 4.
SCNX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.78 | 20% below |
| 20 week MA | $7.26 | 59% below |
| 50 week MA | $9.55 | 68% below |
| 100 week MA | $28.1 | 89% below |
SCNX is in a downtrend: it's below all four of its weekly moving averages, and 89% below its 100-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over SCNX on returns for 2026, with the stronger performance.
SCNX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $197.5 | $155.0 | -22% |
| 2025 | $155.0 | $12.6 | -92% |
| 2026 YTD | $12.6 | $3.01 | -76% |
SCNX has finished every year since 2024 lower, and it's down 76% so far in 2026.